Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleOMERACT 10: 10th International Consensus Conference on Outcome Measures in Rheumatology, Kota Kinabalu, Borneo - May 4–8, 2010

Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?

LISA K. STAMP, PUJA P. KHANNA, NICOLA DALBETH, MAARTEN BOERS, WALTER P. MAKSYMOWYCH, H. RALPH SCHUMACHER Jr, MICHAEL A. BECKER, PATRICIA A. MacDONALD, N. LAWRENCE EDWARDS, JASVINDER A. SINGH, LEE S. SIMON, FIONA M. McQUEEN, TUHINA NEOGI, ANGELO L. GAFFO, VIBEKE STRAND and WILLIAM J. TAYLOR
The Journal of Rheumatology July 2011, 38 (7) 1462-1466; DOI: https://doi.org/10.3899/jrheum.110273
LISA K. STAMP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lisa.stamp@cdhb.govt.nz
PUJA P. KHANNA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICOLA DALBETH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAARTEN BOERS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WALTER P. MAKSYMOWYCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. RALPH SCHUMACHER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL A. BECKER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PATRICIA A. MacDONALD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. LAWRENCE EDWARDS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JASVINDER A. SINGH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LEE S. SIMON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FIONA M. McQUEEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TUHINA NEOGI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANGELO L. GAFFO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VIBEKE STRAND
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WILLIAM J. TAYLOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To summarize evidence for and endorsement of serum urate (SU) as having fulfilled the OMERACT filter as a soluble biomarker in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10).

Methods. Data were presented to support the use of SU as a soluble biomarker in chronic gout and specifically the ability to utilize it to predict future patient-reported outcomes.

Results. SU was accepted as having fulfilled the OMERACT filter by 78% of voters. However, consensus was not obtained regarding its use as a soluble biomarker in chronic gout. Although the majority of the criteria for a soluble biomarker were fulfilled, the key criterion of association of the biomarker with outcomes was not agreed upon. It was agreed that the appropriate choice of endpoint must be linked to its clinical importance to the individual with the disorder and its temporal relationship to the intervention. Appropriate outcomes in chronic gout may therefore include gout flares, reduction in tophi, and patient-reported outcomes.

Conclusion. SU is a critical outcome measure. It has the potential to fulfil criteria for a soluble biomarker. Further analyses of existing data from randomized controlled trials will be required to determine whether SU can predict future important outcomes, in particular disability.

Key Indexing Terms:
  • SERUM URATE
  • GOUT
  • BIOMARKER

Footnotes

  • Supported by National Institutes of Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) to Dr. Singh; and resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. Dr. Neogi was supported by awards from the NIH K23 (AR0557127) and P60 AR047785. Dr. Khanna was supported by research grants from the NIH/NIAMS (UO1 AR057936) and an American College of Rheumatology REF Clinical Investigator Award. Data were obtained from the Savient Pharmaceuticals and the Takeda Global Research and Development. Dr. Schumacher has received consulting fees from Takeda, Savient, Regeneron, Novartis, and Pfizer. Dr. Becker has been a consultant for Takeda, Savient, BioCryst, URL Pharmaceuticals, Ardea, and Regeneron. Ms MacDonald is an employee of Takeda Global Research and Development. Dr. Edwards has received consultant fees from Takeda and Savient. Dr. Singh has received speaker honoraria from Abbott; research and travel grants from Allergan, Takeda, Savient, Wyeth and Amgen; and consultant fees from Savient, URL Pharmaceuticals, and Novartis. Dr. Simon has served on the Board of Directors for Savient Pharmaceuticals and as a consultant for Takeda. Dr. Strand has served as a consultant to Savient and Takeda Pharmaceuticals.

View Full Text

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 38, Issue 7
1 Jul 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
Citation Tools
Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?
LISA K. STAMP, PUJA P. KHANNA, NICOLA DALBETH, MAARTEN BOERS, WALTER P. MAKSYMOWYCH, H. RALPH SCHUMACHER, MICHAEL A. BECKER, PATRICIA A. MacDONALD, N. LAWRENCE EDWARDS, JASVINDER A. SINGH, LEE S. SIMON, FIONA M. McQUEEN, TUHINA NEOGI, ANGELO L. GAFFO, VIBEKE STRAND, WILLIAM J. TAYLOR
The Journal of Rheumatology Jul 2011, 38 (7) 1462-1466; DOI: 10.3899/jrheum.110273

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?
LISA K. STAMP, PUJA P. KHANNA, NICOLA DALBETH, MAARTEN BOERS, WALTER P. MAKSYMOWYCH, H. RALPH SCHUMACHER, MICHAEL A. BECKER, PATRICIA A. MacDONALD, N. LAWRENCE EDWARDS, JASVINDER A. SINGH, LEE S. SIMON, FIONA M. McQUEEN, TUHINA NEOGI, ANGELO L. GAFFO, VIBEKE STRAND, WILLIAM J. TAYLOR
The Journal of Rheumatology Jul 2011, 38 (7) 1462-1466; DOI: 10.3899/jrheum.110273
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Abstract
    • BIOMARKER CRITERIA
    • DISCUSSION AND VOTING
    • CONCLUSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

OMERACT 10: 10th International Consensus Conference on Outcome Measures in Rheumatology, Kota Kinabalu, Borneo - May 4–8, 2010

  • The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) Is Reliable and Sensitive to Change: Results from an OMERACT Workshop
  • The OMERACT Ultrasound Task Force — Status and Perspectives
  • Update on Research and Future Directions of the OMERACT MRI Inflammatory Arthritis Group
Show more OMERACT 10: 10th International Consensus Conference on Outcome Measures in Rheumatology, Kota Kinabalu, Borneo - May 4–8, 2010

Disease-specific Outcomes

  • Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) — Report of the OMERACT 10 PsA Special Interest Group
  • Developing Disease Activity and Response Criteria in Connective Tissue Disease-related Interstitial Lung Disease
  • Toward Development of a Fibromyalgia Responder Index and Disease Activity Score: OMERACT Module Update
Show more Disease-specific Outcomes

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • AV Rheum

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire